Introduction. The multifactorial chylomicronemia ((MCM), also known as type V hyperlipoproteinaemia or mixed hyperlipidaemia) is an oligogenic or polygenic disorder that is associated with a reduction in lipoprotein lipase activity which leads to chylomicronemia. In this disease, very high concentrations of serum triglycerides (≥10 mmol/l (≥880 mg/dL)) can be observed in the fasting state due to the accumulation of both VLDL-C and chylomicron. In patients with MCM, chylomicronemia typically occur in adulthood and is exacerbated by the presence of secondary factors such as a diet rich in dietary fats and simple sugars, obesity, alcohol intake and uncontrolled diabetes. It has been estimated that chylomicronemia can be found in 1:600 adults. However, it is likely that the prevalence of MCM may increase in the future due to the increasing prevalence of obesity, metabolic syndrome and type 2 diabetes. This condition increases the risk of acute pancreatitis, which can be recurrent and potentially fatal. Indeed, the risk of acute pancreatitis is 10-20% for TG levels \> 22.58 mmol/L (\>2000 mg/dL). Furthermore, because MCM patients often present with other lipid disturbances as well as a worse metabolic profile, these patients are at increased risk of cardiovascular disease (CVD). Fortunately, MCM patients generally respond well to modifications in lifestyle, to treatment of secondary factors and to triglycerides lowering therapies such as fibrates. However, it is still unknown which kind of diet has the greatest effect on triglycerides level and on the metabolic profile in MCM patients. The nutritional recommendations can be very different according to the nature of the patient's population to be treated. In order to reduce and manage triglycerides level in the general population, the American Heart Association guidelines recommend reduction of simple carbohydrates intake. On the other hand, the nutritional intervention strategy is quite different for subjects affected by familial chylomicronemia syndrome (FCS), for which the treatment focuses on restriction of dietary fat. FCS is a very rare autosomal recessive disease that leads to a drastic reduction of chylomicrons clearance leading to chylomicronaemia. Therefore, a very strict lipid-controlled diet low in long-chain fatty acid (10-30g/day or 10%-15% of total energy intake) is required in order to lower chylomicron formation. MCM is a complex condition in which both an increased VLDL formation by the liver and a decreased chylomicrons and VLDL clearance are present. Furthermore, triglycerides values are fluctuating from day to day but generally remain very high. Therefore, the best dietary approach for these patients remains to be elucidated. Primary Objective. The primary objective of this study is to compare the effects of low-fat vs low-carbohydrate diets on fasting serum triglyceride concentrations. Secondary Objectives. 1. To compare the effects of low-fat vs low-carbohydrate diets on other fasting cardiometabolic parameters: measured LDL-C, total cholesterol, HDL-C, glucose, insulin, HOMA-IR, apoB, non-HDL-C, hs-CRP, PCSK9 and free fatty acids (FFA). 2. To compare the effects of low-fat vs low-carbohydrate diets on SBP, DBP and waist circumference. 3. To compare the effects of low-fat vs low-carbohydrate diets on lipoprotein subfractions (fasting). 4. To compare the effects of low-fat vs low-carbohydrate meals on postprandial triglycerides, insulin, glucose, FFA and PCSK9 after a standardized test meal. 5. To assess the patients' appreciation, compliance and tolerability for each experimental diet (feedback questionnaire).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
3 weeks
Institut de recherches cliniques de Montreal
Montreal, Quebec, Canada
Change of triglycerides from baseline
Fasting serum triglyceride concentrations (mmol/L)
Time frame: 3 weeks
Change of measured LDL-C from baseline
Fasting measured LDL-C concentrations (mmol/L)
Time frame: 3 weeks
Change of total cholesterol from baseline
Fasting total cholesterol concentrations (mmol/L)
Time frame: 3 weeks
Change of HDL-C from baseline
Fasting HDL-C concentrations (mmol/L)
Time frame: 3 weeks
Change of glucose from baseline
Fasting glucose concentrations (mmol/L)
Time frame: 3 weeks
Change of insulin from baseline
Fasting insulin concentrations (pmol/L)
Time frame: 3 weeks
Change of apolipoprotein B from baseline
Fasting apolipoprotein B concentrations (g/L)
Time frame: 3 weeks
Change of hs-CRP from baseline
Fasting hs-CRP concentrations (mg/L)
Time frame: 3 weeks
Change of PCSK9 from baseline
Fasting PCSK9 concentrations (ng/mL)
Time frame: 3 weeks
Change of free fatty acids from baseline
Fasting free fatty acids concentrations (mEq/L)
Time frame: 3 weeks
Change of systolic blood pressure from baseline
Measurement of systolic blood pressure (mmHg)
Time frame: 3 weeks
Change of diastolic blood pressure from baseline
Measurement of diastolic blood pressure (mmHg)
Time frame: 3 weeks
Change of waist circumference from baseline
Measurement of waist circumference (cm)
Time frame: 3 weeks
Change in the composition of lipoprotein fractions from baseline
Ultracentrifugation and lipoprotein electrophoresis
Time frame: 3 weeks
Postprandial triglycerides
After a standardized test meal (1h, 2h, 4h and 6h) (mmol/L)
Time frame: One day
Postprandial insulin
After a standardized test meal (1h, 2h, 4h and 6h) (pmol/L)
Time frame: One day
Postprandial glucose
After a standardized test meal (1h, 2h, 4h and 6h) (mmol/L)
Time frame: One day
Postprandial free fatty acids
After a standardized test meal (1h, 2h, 4h and 6h) (mEq/L)
Time frame: One day
Postprandial PCSK9
After a standardized test meal (1h, 2h, 4h and 6h) (ng/mL)
Time frame: One day
Questionnaire of appreciation, compliance and tolerability
The patients' appreciation, compliance and tolerability for each experimental diet will be collected in a questionnaire
Time frame: 3 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.